Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 15, 2019

FDA declines to approve Motif Bio’s iclaprim for ABSSSI treatment

The US Food & Drug Administration (FDA) has refused to give its approval to Motif Bio’s skin disorder drug iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA declines to approve Motif Bio’s iclaprim for ABSSSI treatment